Actavis receives final FDA authorization for Zolpidem ER Tablets Actavis.

Actavis receives final FDA authorization for Zolpidem ER Tablets Actavis, an international generic pharmaceuticals organization, today announced that it has received final approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Launch Tablets USP, 12.5 mg CIV.5 mg enables Actavis to offer both strengths to meet the requirements of our customers.’.It hopes to have at least 100,000 employees enrolled by early next year .This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Base. Kaiser Health News, an independent news service editorially, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.. Ablative Solutions completes $9.5M Series B Preferred Share financing Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, today that it has completed a Series B Preferred Stock financing announced, totaling approximately $9.5 million , to fund its unique technology system for renal denervation.